Ketamine hydrochloride is under clinical development by Seelos Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ketamine hydrochloride’s likelihood of approval (LoA) and phase transition for Post-Traumatic Stress Disorder (PTSD) took place on 16 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ketamine hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ketamine hydrochloride overview

Ereska (intranasal ketamine, PMI-150, SLS-002) is under development for the treatment of suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The drug candidate is administered through intranasal route. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA) and glutamate ionotropic receptor NMDA type subunit.

It was also under development for the treatment of postoperative pain and pain in cancer patients.

Seelos Therapeutics overview

Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.

Quick View Ketamine hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Ketamine hydrochloride
Administration Pathway
  • Nasal
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.